U.S. Pharmaceuticals & Biotech Mid-Large Cap Stocks

Bristol-Myers Squibb

Market Cap: US$117.6b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Johnson & Johnson

Market Cap: US$618.6b

Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Zoetis

Market Cap: US$31.7b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Amgen

Market Cap: US$196.1b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Gilead Sciences

Market Cap: US$161.2b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Merck

Market Cap: US$305.1b

Operates as a healthcare company worldwide.

AbbVie

Market Cap: US$438.3b

A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Phibro Animal Health

Market Cap: US$1.3b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Agilent Technologies

Market Cap: US$37.9b

Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

Pfizer

Market Cap: US$137.8b

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Perrigo

Market Cap: US$1.4b

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.

Danaher

Market Cap: US$140.9b

Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Royalty Pharma

Market Cap: US$32.5b

Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

Qiagen

Market Cap: US$8.6b

Provides sample to insight solutions that transform biological samples into molecular insights worldwide.

Viatris

Market Cap: US$18.9b

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

AnaptysBio

Market Cap: US$2.0b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Hisamitsu Pharmaceutical

Market Cap: US$8.2b

Manufactures and sells pharmaceuticals in Japan.

Exelixis

Market Cap: US$14.2b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Illumina

Market Cap: US$28.8b

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Trevi Therapeutics

Market Cap: US$2.5b

A clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.

TG Therapeutics

Market Cap: US$8.1b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Sarepta Therapeutics

Market Cap: US$2.0b

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Alnylam Pharmaceuticals

Market Cap: US$39.9b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Capricor Therapeutics

Market Cap: US$1.2b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Arcus Biosciences

Market Cap: US$3.6b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Amylyx Pharmaceuticals

Market Cap: US$2.0b

A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

ADMA Biologics

Market Cap: US$2.1b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

BioNTech

Market Cap: US$23.1b

Engages in the development and commercialization of immunotherapies in Germany.

ACADIA Pharmaceuticals

Market Cap: US$4.5b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

UroGen Pharma

Market Cap: US$1.9b

A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

Corcept Therapeutics

Market Cap: US$9.9b

A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Medpace Holdings

Market Cap: US$15.4b

Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

Septerna

Market Cap: US$1.6b

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

Biogen

Market Cap: US$29.4b

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Pacira BioSciences

Market Cap: US$1.0b

Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

Olema Pharmaceuticals

Market Cap: US$1.0b

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.